• Gene fusion; HGNC; HGNC:3689; FGFR2 + HGNC; HGNC:17142; OPTN; Name(s)=FGFR2-OPTN; Note=In frame. FGFR2 exon 17 fused to OPTN exon 9 (PubMed=31109923).
  

PubMed=31109923; DOI=10.1158/2159-8290.CD-19-0182; PMCID=PMC6677584
Goyal L., Shi L., Liu L.Y., Fece de la Cruz F., Lennerz J.K., Raghavan S., Leschiner I., Elagina L., Siravegna G., Ng R.W.S., Vu P., Patra K.C., Saha S.K., Uppot R.N., Arellano R.S., Reyes S., Sagara T., Otsuki S., Nadres B., Shahzade H.A., Dey-Guha I., Fetter I.J., Baiev I., Van Seventer E.E., Murphy J.E., Ferrone C.R., Tanabe K.K., Deshpande V., Harding J.J., Yaeger R.D., Kelley R.K., Bardelli A., Iafrate A.J., Hahn W.C., Benes C.H., Ting D.T., Hirai H., Getz G., Juric D., Zhu A.X.-X., Corcoran R.B., Bardeesy N.M.
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.
Cancer Discov. 9:1064-1079(2019)

PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448
Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L., Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J., Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L., Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J., Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E., Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W., Vazquez F., Getz G., Bardeesy N.M.
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
bioRxiv 2024:07.04.601970-07.04.601970(2024)